1841O - Second/third-line nivolumab vs nivo plus ipilimumab in malignant pleural mesothelioma: Long-term results of IFCT-1501 MAPS2 phase IIR trial with a focus on hyperprogression (HPD)
| Autor: | Zalcman, G. 1, Mazieres, J. 2, Greillier, L. 3, Brosseau, S. 1, Lantuejoul, S. 4, Do, P. 5, Bylicki, O. 6, Monnet, I. 7, Corre, R. 8, Audigier-Valette, C. 9, Locatelli-Sanchez, M. 10, Molinier, O. 11, Guisier, F. 12, Urban, T. 13, Planchard, D. 14, Ligeza-Poisson, C. 15, Amour, E. 16, Morin, F. 16, Moro-Sibilot, D. 17, Scherpereel, A. 18 |
|---|---|
| Zdroj: | In Annals of Oncology October 2019 30 Supplement 5:v747-v747 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|